यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, timolol maleate - glaucoma, open-angle; ocular hypertension - oftalmologi - zmanjšanje intraokularnega tlaka (iop) pri odraslih bolnikih z glavkomom odprtega zakotja ali očesno hipertenzijo, pri kateri monoterapija ne zagotavlja zadostnega znižanja iop.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

sandoz gmbh - epoetin alfa - anemia; kidney failure, chronic - antianemični preparati - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. srca in ožilja, stanja, predhodno obstoječe anemija na začetku kemoterapijo).

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zdravila za obstruktivne pljučne bolezni, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za spreminjanje lipidov - cholib je označen kot dodatno zdravljenje prehrana in telesno vadbo v visokim tveganjem kardiovaskularnih odraslih bolnikih z mešano dyslipidaemia za zmanjšanje trigliceridov in povečanje hdl c ravni, ko ravni ldl c ustrezno nadzorovana z ustreznim odmerkom simvastatin monoterapije.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmentu višinskih akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za nadaljnje informacije, prosimo, preberite razdelek 5.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotična sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zdravila za obstruktivne pljučne bolezni, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemični preparati - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. , zdravljenje anemija) in zmanjšanje transfuzijo zahteve pri odraslih bolnikih, ki prejemajo kemoterapijo za trdne tumorje, maligni limfom ali več plazmocitom, in na tveganje za transfuzijo, kot jo je ocenil bolnikovo splošno stanje (e. srca in ožilja, stanja, predhodno obstoječe anemija na začetku kemoterapijo).

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertapenem natrij - community-acquired infections; streptococcal infections; staphylococcal infections; gram-negative bacterial infections; surgical wound infection; pneumonia, bacterial - antibacterials za sistemsko uporabo, - treatmenttreatment naslednjih okužb pri povzročajo bakterije znano, ali je zelo verjetno, da je dovzetna za ertapenem in ko parenteral terapija je potrebna:znotraj trebušne okužb;skupnosti, pridobljena pljučnica;akutna ginekološka okužb;diabetično stopalo okužbe kože in mehkih tkiv. preventioninvanz je navedeno v odraslim za preventivo kirurške mesto okužbe naslednje izbirne kirurgija debelega črevesa in danke. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

pfizer europe ma eeig - levetiracetam - epilepsija - antiepileptics, - levetiracetam hospira je označen kot monoterapije pri zdravljenju zasegov delno nastopa z ali brez sekundarnega posplošitev v odrasli in mladostniki, od 16 let z novo diagnosticirano epilepsijo. levetiracetam hospira je označen kot adjunctive therapyin zdravljenje delno nastop napadi z ali brez sekundarne posplošitev pri odraslih, mladostnikih in otrocih od 4 let z epilepsijo. pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsijo. v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo. levetiracetam hospira koncentrat je alternativa za bolnike, ko ustni uprava je začasno ni izvedljivo,.